Trained immunity emerges as key driver of diabetes and complications

Diabetes has long been understood as a disease of blood sugar gone wrong. But a new review in the journal Genes & Diseases suggests the story is far more complicated—and that the immune system itself may be driving much of the damage that high glucose alone cannot explain.

The culprit is something called trained immunity, a form of lasting adaptation in the body's innate immune cells. When monocytes and macrophages—the immune system's first responders—encounter metabolic stress or inflammatory signals, they don't simply react and move on. Instead, they become permanently altered, primed to mount more aggressive responses to future challenges. The result is a state of chronic inflammation that can persist long after the original trigger has vanished. This phenomenon, the review argues, directly links the metabolic chaos of diabetes to the immune system's behavior.

The connection runs deep. High blood sugar, obesity, abnormal lipid levels, and shifts in the gut microbiome—all hallmarks of diabetes—can activate these trained immunity pathways. Once activated, the resulting inflammatory cascade promotes insulin resistance, damages the insulin-producing beta cells in the pancreas, and accelerates injury throughout the body. Diabetes already affects hundreds of millions of people worldwide and stands as a leading cause of cardiovascular disease, kidney disease, vision loss, and other serious complications. But if trained immunity is amplifying this damage, it means the disease is more than a glucose problem.

The effects ripple outward. Evidence in the review suggests that trained immunity may accelerate atherosclerosis, the hardening of arteries that leads to heart attacks and strokes. It may worsen diabetic kidney disease, the leading cause of kidney failure in developed countries. It may impair wound healing, leaving diabetic patients vulnerable to infections and tissue damage. Across multiple organs, persistent immune activation appears to drive tissue injury, scarring, vascular dysfunction, and the chronic inflammation that characterizes diabetes and its complications.

What makes this understanding significant is not merely academic. It opens new therapeutic doors. Rather than focusing solely on lowering blood glucose, researchers are now exploring ways to interrupt the trained immunity cascade itself. Some approaches target the NLRP3 inflammasome, a molecular trigger of inflammation. Others aim to reshape cellular metabolism or restore balance to the gut microbiome through diet and microbiome-focused therapies. Still others investigate vaccination strategies that could reprogram immune cells before they become locked into a pro-inflammatory state.

The review, authored by researchers including Qiming Gong, Yuqing Huang, and colleagues, represents a shift in how the scientific community thinks about diabetes. For decades, the focus has been on insulin and glucose. Now, the immune system itself is emerging as a central player in disease development and progression. If these new therapeutic approaches prove effective, they could address not just the symptoms of diabetes but the underlying immune mechanisms that drive it forward—potentially transforming how millions of patients are treated.